Open access · CC-BY
via OpenAlex
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Salihanur Darici, Hazem Alkhaldi, Gillian Abigail Horne, Heather G. Jørgensen, Sandra Marmiroli, Xu Huang
Journal of Clinical Medicine · 2020 · ▲ 137 citations
Deregulated nutrient-sensing
Stem-cell exhaustion
Altered intercellular communication
Rapamycin / mTOR inhibition
Human
Review
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted therapy is required. Persistent leukemia stem cell (LSC) populations underlie patient relapse and development of resistance to therapy. Identification of critical oncogenic signaling pathways in AML LSC may provide new avenues for novel therapeutic strategies. The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) signaling pathway, is often hyperactivated in AML, required to sustain the oncogenic potential of LSCs. Growing evidence suggests that targeting key components of this pathway may represent an effective treatment to kill AML LSCs. Despite this, accruing significant body of scientific knowledge, PI3K/Akt/mTOR inhibitors have not translated into clinical practice. In this article, we review the laboratory-based evidence of the critical role of PI3K/Akt/mTOR pathway in AML, and outcomes from current clinical studies using PI3K/Akt/mTOR inhibitors. Based on these results, we discuss the putative mechanisms of resistance to PI3K/Akt/mTOR inhibition, offering rationale for potential candidate combination therapies incorporating PI3K/Akt/mTOR inhibitors for precision medicine in AML.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/jcm9092934
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Darici, S., Alkhaldi, H., Horne, G.A., Jørgensen, H.G., Marmiroli, S., & Huang, X. (2020). Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <em>Journal of Clinical Medicine</em>. https://doi.org/10.3390/jcm9092934
Vancouver
Darici S, Alkhaldi H, Horne GA, Jørgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. Journal of Clinical Medicine. 2020. doi:10.3390/jcm9092934.
BibTeX
@article{salihanur2020Target,
title = {Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence},
author = {Salihanur Darici and Hazem Alkhaldi and Gillian Abigail Horne and Heather G. Jørgensen and Sandra Marmiroli and Xu Huang},
journal = {Journal of Clinical Medicine},
year = {2020},
doi = {10.3390/jcm9092934},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Oncotarget 2010
Open access · OA
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Signal Transduction and Targeted Therapy 2021
Open access · CC-BY
Targeting PI3K/Akt signal transduction for cancer therapy
Annals of Medicine 2014
Open access · OA
PI3K/AKT signaling pathway and cancer: an updated review
Cells 2023
Open access · CC-BY
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
International Journal of Molecular Sciences 2021
Open access · CC-BY
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Cells 2019
Open access · CC-BY